Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative EMDA Mitomycin-C in Non-Muscle Invasive Bladder Cancer
2024-510867-42-00Phase 4Authorised
- Sponsor
- Foundation for the Incentive of Research
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mitomycin c in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Foundation for the Incentive of Research. Primary endpoints: Recurrence-free survival and Progression-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
mitomycin c
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2024-510867-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510867-42-00.